Advertisement

New immunosuppressive approaches: Oral administration of CD3-specific antibody to treat autoimmunity

      Abstract

      One of the major goals for the immunotherapy of autoimmune diseases is the induction of regulatory T cells that mediate immunologic tolerance. Parenteral administration of anti-CD3 monoclonal antibody is an approved therapy for transplantation in humans and is effective in autoimmune diabetes. We have found that oral administration of anti-CD3 monoclonal antibody is biologically active in the gut and suppresses experimental autoimmune encephalomyelitis both prior to disease induction and at the height of disease. Oral anti-CD3 antibody acts by inducing a unique type of regulatory T cell characterized by latency-associated peptide (LAP) on its cell surface that functions in vivo and in vitro via TGF-β dependent mechanism. Orally delivered antibody would not have side effects including cytokine release syndromes, thus oral anti-CD3 antibody is clinically applicable for chronic therapy. These findings identify a novel and powerful immunologic approach that is widely applicable for the treatment of human autoimmune conditions.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Schwartz R.H.
        Acquisition of immunologic self-tolerance.
        Cell. 1989; 57: 1073-1081
        • Herold K.C.
        • Bluestone J.A.
        • Montag A.G.
        • Parihar A.
        • Wiegner A.
        • Gress R.E.
        • et al.
        Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody.
        Diabetes. 1992; 41: 385-391
        • Chatenoud L.
        • Thervet E.
        • Primo J.
        • Bach J.F.
        Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
        Proc Natl Acad Sci U S A. 1994; 91: 123-127
        • Chatenoud L.
        • Primo J.
        • Bach J.F.
        CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice.
        J Immunol. 1997; 158: 2947-2954
        • Mottram P.L.
        • Murray-Segal L.J.
        • Han W.
        • Maguire J.
        • Stein-Oakley A.N.
        Remission and pancreas isograft survival in recent onset diabetic NOD mice after treatment with low-dose anti-CD3 monoclonal antibodies.
        Transpl Immunol. 2002; 10: 63-72
        • von Herrath M.G.
        • Coon B.
        • Wolfe T.
        • Chatenoud L.
        Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance.
        J Immunol. 2002; 168: 933-941
        • Belghith M.
        • Bluestone J.A.
        • Barriot S.
        • Megret J.
        • Bach J.F.
        • Chatenoud L.
        TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.
        Nat Med. 2003; 9: 1202-1208
        • Tran G.T.
        • Carter N.
        • He X.Y.
        • Spicer T.S.
        • Plain K.M.
        • Nicolls M.
        • et al.
        Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4.
        Int Immunol. 2001; 13: 1109-1120
        • Kohm A.P.
        • Williams J.S.
        • Bickford A.L.
        • McMahon J.S.
        • Chatenoud L.
        • Bach J.F.
        • et al.
        Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis.
        J Immunol. 2005; 174: 4525-4534
        • Herold K.C.
        • Hagopian W.
        • Auger J.A.
        • Poumian-Ruiz E.
        • Taylor L.
        • Donaldson D.
        • et al.
        Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
        N Engl J Med. 2002; 346: 1692-1698
        • Herold K.C.
        • Burton J.B.
        • Francois F.
        • Poumian-Ruiz E.
        • Glandt M.
        • Bluestone J.A.
        Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).
        J Clin Invest. 2003; 111: 409-418
        • Herold K.C.
        • Gitelman S.E.
        • Masharani U.
        • Hagopian W.
        • Bisikirska B.
        • Donaldson D.
        • et al.
        A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
        Diabetes. 2005; 54: 1763-1769
        • Keymeulen B.
        • Vandemeulebroucke E.
        • Ziegler A.G.
        • Mathieu C.
        • Kaufman L.
        • Hale G.
        • et al.
        Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
        N Engl J Med. 2005; 352: 2598-2608
        • Utset T.O.
        • Auger J.A.
        • Peace D.
        • Zivin R.A.
        • Xu D.
        • Jolliffe L.
        • et al.
        Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial.
        J Rheumatol. 2002; 29: 1907-1913
        • Chatenoud L.
        • Baudrihaye M.F.
        • Kreis H.
        • Goldstein G.
        • Schindler J.
        • Bach J.F.
        Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody.
        Eur J Immunol. 1982; 12: 979-982
        • Chatenoud L.
        • Baudrihaye M.F.
        • Chkoff N.
        • Kreis H.
        • Goldstein G.
        • Bach J.F.
        Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3.
        J Immunol. 1986; 137: 830-838
        • Chatenoud L.
        Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation.
        Curr Opin Pharmacol. 2004; 4: 403-407
        • Chatenoud L.
        CD3-specific antibodies as promising tools to aim at immune tolerance in the clinic.
        Int Rev Immunol. 2006; 25: 215-233
        • Chatenoud L.
        CD3-specific antibody-induced active tolerance: from bench to bedside.
        Nat Rev Immunol. 2003; 3: 123-132
        • Chatenoud L.
        • Bluestone J.A.
        CD3-specific antibodies: a portal to the treatment of autoimmunity.
        Nat Rev Immunol. 2007; 7: 622-632
        • Chatenoud L.
        CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications.
        Curr Opin Immunol. 2005; 17: 632-637
        • Chen Y.
        • Kuchroo V.K.
        • Inobe J.
        • Hafler D.A.
        • Weiner H.L.
        Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis.
        Science. 1994; 265: 1237-1240
        • Zhang X.
        • Izikson L.
        • Liu L.
        • Weiner H.L.
        Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration.
        J Immunol. 2001; 167: 4245-4253
        • Sayegh M.H.
        • Khoury S.J.
        • Hancock W.W.
        • Weiner H.L.
        • Carpenter C.B.
        Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat.
        Proc Natl Acad Sci U S A. 1992; 89: 7762-7766
        • Miller A.
        • al-Sabbagh A.
        • Santos L.M.
        • Das M.P.
        • Weiner H.L.
        Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression.
        J Immunol. 1993; 151: 7307-7315
        • Maron R.
        • Melican N.S.
        • Weiner H.L.
        Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally- and nasally-treated NOD mice suppress diabetes.
        J Autoimmun. 1999; 12: 251-258
        • Inobe J.
        • Slavin A.J.
        • Komagata Y.
        • Chen Y.
        • Liu L.
        • Weiner H.L.
        IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis.
        Eur J Immunol. 1998; 28: 2780-2790
        • Slavin A.J.
        • Maron R.
        • Weiner H.L.
        Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes.
        Int Immunol. 2001; 13: 825-833
        • Plain K.M.
        • Chen J.
        • Merten S.
        • He X.Y.
        • Hall B.M.
        Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: association with TH2 cytokines not anergy.
        Transplantation. 1999; 67: 605-613
        • Kung P.
        • Goldstein G.
        • Reinherz E.L.
        • Schlossman S.F.
        Monoclonal antibodies defining distinctive human T cell surface antigens.
        Science. 1979; 206: 347-349
        • Cosimi A.B.
        • Colvin R.B.
        • Burton R.C.
        • Rubin R.H.
        • Goldstein G.
        • Kung P.C.
        • et al.
        Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts.
        N Engl J Med. 1981; 305: 308-314
        • Hirsch R.
        • Gress R.E.
        • Pluznik D.H.
        • Eckhaus M.
        • Bluestone J.A.
        Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells.
        J Immunol. 1989; 142: 737-743
        • Van Wauwe J.P.
        • De Mey J.R.
        • Goossens J.G.
        OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties.
        J Immunol. 1980; 124: 2708-2713
        • Ferran C.
        • Sheehan K.
        • Dy M.
        • Schreiber R.
        • Merite S.
        • Landais P.
        • et al.
        Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation.
        Eur J Immunol. 1990; 20: 509-515
        • Alegre M.
        • Vandenabeele P.
        • Flamand V.
        • Moser M.
        • Leo O.
        • Abramowicz D.
        • et al.
        Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor.
        Eur J Immunol. 1990; 20: 707-710
        • Chatenoud L.
        • Legendre C.
        • Ferran C.
        • Bach J.F.
        • Kreis H.
        Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome-dosage and kinetics prerequisites.
        Transplantation. 1991; 51: 334-338
        • Chatenoud L.
        • Ferran C.
        • Bach J.F.
        The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation.
        Curr Top Microbiol Immunol. 1991; 174: 121-134
        • Abramowicz D.
        • Schandene L.
        • Goldman M.
        • Crusiaux A.
        • Vereerstraeten P.
        • De Pauw L.
        • et al.
        Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients.
        Transplantation. 1989; 47: 606-608
        • Van Lier R.A.
        • Boot J.H.
        • De Groot E.R.
        • Aarden L.A.
        Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems.
        Eur J Immunol. 1987; 17: 1599-1604
        • Hirsch R.
        • Bluestone J.A.
        • DeNenno L.
        • Gress R.E.
        Anti-CD3 F(ab′)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb.
        Transplantation. 1990; 49: 1117-1123
        • Parlevliet K.J.
        • ten Berge I.J.
        • Yong S.L.
        • Surachno J.
        • Wilmink J.M.
        • Schellekens P.T.
        In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.
        J Clin Invest. 1994; 93: 2519-2525
        • Bolt S.
        • Routledge E.
        • Lloyd I.
        • Chatenoud L.
        • Pope H.
        • Gorman S.D.
        • et al.
        The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.
        Eur J Immunol. 1993; 23: 403-411
        • Hughes C.
        • Wolos J.A.
        • Giannini E.H.
        • Hirsch R.
        Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody.
        J Immunol. 1994; 153: 3319-3325
        • Alegre M.L.
        • Peterson L.J.
        • Xu D.
        • Sattar H.A.
        • Jeyarajah D.R.
        • Kowalkowski K.
        • et al.
        A non-activating “humanized” anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
        Transplantation. 1994; 57: 1537-1543
        • Johnson B.D.
        • McCabe C.
        • Hanke C.A.
        • Truitt R.L.
        Use of anti-CD3 epsilon F(ab′)2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation.
        J Immunol. 1995; 154: 5542-5554
        • Smith J.A.
        • Tso J.Y.
        • Clark M.R.
        • Cole M.S.
        • Bluestone J.A.
        Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy.
        J Exp Med. 1997; 185: 1413-1422
        • Smith J.A.
        • Tang Q.
        • Bluestone J.A.
        Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets.
        J Immunol. 1998; 160: 4841-4849
        • Bisikirska B.
        • Colgan J.
        • Luban J.
        • Bluestone J.A.
        • Herold K.C.
        TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs.
        J Clin Invest. 2005; 115: 2904-2913
        • Friend P.J.
        • Hale G.
        • Chatenoud L.
        • Rebello P.
        • Bradley J.
        • Thiru S.
        • et al.
        Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection.
        Transplantation. 1999; 68: 1632-1637
        • Woodle E.S.
        • Xu D.
        • Zivin R.A.
        • Auger J.
        • Charette J.
        • O'Laughlin R.
        • et al.
        Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
        Transplantation. 1999; 68: 608-616
        • Nicolls M.R.
        • Aversa G.G.
        • Pearce N.W.
        • Spinelli A.
        • Berger M.F.
        • Gurley K.E.
        • et al.
        Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody.
        Transplantation. 1993; 55: 459-468
        • Blazar B.R.
        • Jenkins M.K.
        • Taylor P.A.
        • White J.
        • Panoskaltsis-Mortari A.
        • Korngold R.
        • et al.
        Anti-CD3 epsilon F(ab′)2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen.
        J Immunol. 1997; 159: 5821-5833
        • Blazar B.R.
        • Taylor P.A.
        • Vallera D.A.
        In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
        J Immunol. 1994; 152: 3665-3674
        • Ochi H.
        • Abraham M.
        • Ishikawa H.
        • Frenkel D.
        • Yang K.
        • Basso A.S.
        • et al.
        Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25−LAP+ T cells.
        Nat Med. 2006; 12: 627-635
        • Weinshenker B.G.
        • Bass B.
        • Karlik S.
        • Ebers G.C.
        • Rice G.P.
        An open trial of OKT3 in patients with multiple sclerosis.
        Neurology. 1991; 41: 1047-1052
        • Oida T.
        • Zhang X.
        • Goto M.
        • Hachimura S.
        • Totsuka M.
        • Kaminogawa S.
        • et al.
        CD4+CD25− T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism.
        J Immunol. 2003; 170: 2516-2522
        • Zhang X.
        • Reddy J.
        • Ochi H.
        • Frenkel D.
        • Kuchroo V.K.
        • Weiner H.L.
        Recovery from experimental allergic encephalomyelitis is TGF-beta dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells.
        Int Immunol. 2006; 18: 495-503
        • Friedman A.
        • Weiner H.L.
        Induction of anergy or active suppression following oral tolerance is determined by antigen dosage.
        Proc Natl Acad Sci U S A. 1994; 91: 6688-6692
        • Chen Y.
        • Inobe J.
        • Marks R.
        • Gonnella P.
        • Kuchroo V.K.
        • Weiner H.L.
        Peripheral deletion of antigen-reactive T cells in oral tolerance.
        Nature. 1995; 376: 177-180
        • Carrier Y.
        • Yuan J.
        • Kuchroo V.K.
        • Weiner H.L.
        Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice.
        J Immunol. 2007; 178: 179-185
        • Ishikawa H.
        • Ochi H.
        • Chen M.L.
        • Frenkel D.
        • Maron R.
        • Weiner H.L.
        Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.
        Diabetes. 2007; 56: 2103-2109
      1. Wu HF, Quintana F, Weiner HL. Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10 secreting CD4+CD25-LAP+regulatory T cell and is associated with downregulation of IL-17+CD4+ICOS+CXCR5+ follicular helper T cells. J Immunol in press.

        • Tacket C.O.
        • Losonsky G.
        • Link H.
        • Hoang Y.
        • Guesry P.
        • Hilpert H.
        • et al.
        Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli.
        N Engl J Med. 1988; 318: 1240-1243
        • Shoelson S.E.
        • Lee J.
        • Goldfine A.B.
        Inflammation and insulin resistance.
        J Clin Invest. 2006; 116: 1793-1801